A growing awareness about brain health and Alzheimer's disease in the general population
is leading to an increasing number of cognitively unimpaired individuals, who are concerned …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

The so-called amyloid hypothesis, that the accumulation and deposition of oligomeric or
fibrillar amyloid β (Aβ) peptide is the primary cause of Alzheimer's disease (AD), has been …

The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

Alzheimer's disease (AD) is characterized by two major pathological lesions in the brain,
amyloid plaques and neurofibrillary tangles (NFTs) composed mainly of amyloid-β (Aβ) …

Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

Abstract See Hansson and Mormino (doi: 10.1093/brain/awy065) for a scientific commentary
on this article. Our objective was to compare different whole-brain and region-specific …

Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease
and related human tauopathies. There is a growing body of evidence indicating that …

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …

Importance Apolipoprotein E ε4 (APOEε4) is the single most important genetic risk factor for
Alzheimer disease. WhileAPOEε4is associated with increased amyloid-β burden, its …